Stock Events

Stock Events

Camurus AB 

€51.50
41
-€1.35-2.55% 11:31 Today

Statistics

Day High
6.86
Day Low
6.84
52W High
67.55
52W Low
6.84
Volume
0
Avg. Volume
576
Mkt Cap
3.12B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q4 2025
Q2 2026
Next
0.15
0.22
0.29
0.36
Expected EPS
0.36335878194000004
Actual EPS
N/A

Financials

32.43%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
206.32MRevenue
66.91MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 7CA.STU. It's not an investment recommendation.
Microsoft
7
MSFT
NVIDIA
7
NVDA
Amazon
5
AMZN
Novo Nordisk
5
NOVO-B.CO

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alkermes
ALKS
Mkt Cap7.73B
Alkermes plc develops extended-release injectable and oral products for the treatment of prevalent and chronic diseases, similar to Camurus' focus on long-acting injectable treatments for various conditions.
Indivior Pharmaceuticals
INDV
Mkt Cap4.79B
Indivior PLC specializes in developing medications for addiction and serious mental illnesses, competing directly with Camurus' treatments in the opioid dependence sector.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap42.37B
Teva Pharmaceutical Industries Limited, a larger generic and specialty pharmaceutical company, competes across several areas, including the development of treatments for disorders that Camurus also targets.
Johnson & Johnson
JNJ
Mkt Cap663.28B
Johnson & Johnson, through its pharmaceutical segment Janssen, competes in the development of innovative treatments for disorders in areas such as psychiatry, where Camurus is also active.
Novartis
NVS
Mkt Cap304.1B
Novartis AG, a global healthcare company, has a broad portfolio that includes treatments for neurological conditions, directly competing with some of Camurus' therapeutic areas.
Pfizer
PFE
Mkt Cap162.16B
Pfizer Inc. operates in various therapeutic areas, including those targeted by Camurus, making it a competitor in the pharmaceutical and biotech space.
Abbvie
ABBV
Mkt Cap453.19B
AbbVie Inc. competes with Camurus through its comprehensive portfolio in areas like neuroscience, where Camurus also operates.
Merck
MRK
Mkt Cap370.89B
Merck & Co., Inc. offers products in various therapeutic areas, including infectious diseases and oncology, competing with Camurus' research and development in similar fields.
Bristol-Myers Squibb
BMY
Mkt Cap136.49B
Bristol-Myers Squibb Company has a diverse portfolio in areas like immunoscience, which could overlap with Camurus' work in developing treatments for complex diseases.
GSK
GSK
Mkt Cap99.96B
GlaxoSmithKline plc, with its focus on pharmaceuticals, vaccines, and consumer healthcare, competes in the broader healthcare market, including areas targeted by Camurus.

About

Camurus AB operates as a research based pharmaceutical company. The firm engages in the research, development and commercialization of specialty medicines. It provides its products for the treatment of severe and chronic conditions, which includes opioid dependence, pain, cancer and endocrine disorders. The company was founded by Kare Larsson in 1991 and is headquartered in Lund, Sweden.
Show more...
CEO
Sven Fredrik Tiberg
Employees
285
Country
Sweden
ISIN
SE0007692850
WKN
000A2ABG7

Listings

LSE
GB
0RD1.LSE
STU
DE
7CA.STU
ST
SE
CAMX.ST
F
DE
7CA.F

0 Comments

Share your thoughts

FAQ

What is Camurus AB stock price today?▼
The current price of 7CA.STU is €51.50 EUR — it has decreased by -2.55% in the past 24 hours. Watch Camurus AB stock price performance more closely on the chart.
What is Camurus AB stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Camurus AB stocks are traded under the ticker 7CA.STU.
Is Camurus AB stock price growing?▼
7CA.STU stock has fallen by -3.2% compared to the previous week, the month change is a -7.54% fall, over the last year Camurus AB has showed a -22.73% decrease.
What is Camurus AB market cap?▼
Today Camurus AB has the market capitalization of 3.12B
When is the next Camurus AB earnings date?▼
Camurus AB is going to release the next earnings report on November 05, 2026.
What were Camurus AB earnings last quarter?▼
7CA.STU earnings for the last quarter are 0.36 EUR per share, whereas the estimation was 0.29 EUR resulting in a +25.98% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Camurus AB revenue for the last year?▼
Camurus AB revenue for the last year amounts to 206.32M EUR.
What is Camurus AB net income for the last year?▼
7CA.STU net income for the last year is 66.91M EUR.
How many employees does Camurus AB have?▼
As of September 09, 2026, the company has 285 employees.
In which sector is Camurus AB located?▼
Camurus AB operates in the Health & Wellness sector.
When did Camurus AB complete a stock split?▼
Camurus AB has not had any recent stock splits.
Where is Camurus AB headquartered?▼
Camurus AB is headquartered in Lund, Sweden.